| 1. |
文富强. GOLD 2017 更新与中国慢性阻塞性肺疾病诊治实践. 中华医学杂志, 2017, 97(38): 2967-2971.
|
| 2. |
申永春, 文富强. 2016 年慢性阻塞性肺疾病全球创议更新解读. 中国实用内科杂志, 2016, 36(5): 382-384.
|
| 3. |
The Global Initiative for Chronic Obstructive Lung Disease. GOLD 2017 global strategy for the diagnosis, management and prevention of COPD. (2017-02-10)[2017-10-10]. http://goldcopd.org/gold-2017-global-strategy-diagnosis-management-prevention-copd/.
|
| 4. |
郑劲平. 慢性阻塞性肺疾病的肺功能检查中 FEV1 与 IC 的临床应用. 中国实用内科杂志, 2014(增刊 1): 1-4.
|
| 5. |
US Preventive Services Task Force (USPSTF), Siu AL, Bibbins-Domingo K, et al. Screening for chronic obstructive pulmonary disease: US preventive services task force recommendation statement. JAMA, 2016, 315(13): 1372-1377.
|
| 6. |
Han MK, Muellerova H, Curran-Everett D, et al. GOLD 2011 disease severity classification in COPDGene: a prospective cohort study. Lancet Respir Med, 2013, 1(1): 43-50.
|
| 7. |
Mahler DA, Kerwin E, Ayers T, et al. FLIGHT1 and FLIGHT2: efficacy and safety of QVA149 (Indacaterol/Glycopyrrolate) versus its monocomponents and placebo in patients with chronic obstructive pulmonary disease. Am J RespirCrit Care Med, 2015, 192(9): 1068-1079.
|
| 8. |
Wedzicha JA, Banerji D, Chapman KR, et al. Indacaterol-glycopyrronium versus salmeterol-fluticasone for COPD. N Engl J Med, 2016, 374(23): 2222-2234.
|
| 9. |
Singh D, Papi A, Corradi M, et al. Single inhaler triple therapy versus inhaled corticosteroid plus long-acting β2-agonist therapy for chronic obstructione pulmonary disease (TRILOGY): a double-blind, parallel group, randomized controlled trial. Lancet, 2016, 388(10048): 963-973.
|
| 10. |
Sulaiman I, Cushen B, Greene G, et al. Objective assessment of adherence to inhalers by COPD patients with chronic obstructive pulmonary disease. Am J RespirCrit Care Med, 2017, 195(10): 1333-1343.
|
| 11. |
Watz H, Tetzlaff K, Wouters EF, et al. Blood eosinophil count and exacerbations in severe chronic obstructive pulmonary disease after withdrawal of inhaled corticosteroids: a post-hoc analysis of the WISDOM trial. Lancet Respir Med, 2016, 4(5): 390-398.
|
| 12. |
Pascoe S, Locantore N, Dransfield MT, et al. Blood eosinophil counts, exacerbations, and response to the addition of inhaled fluticasone furoate to vilanterol in patients with chronic obstructive pulmonary disease: a secondary analysis of data from two parallel randomised controlled trials. Lancet Respir Med, 2015, 3(6): 435-442.
|
| 13. |
Pavord ID, Lettis S, Locantore N, et al. Blood eosinophils and inhaled corticosteroid/long-acting β-2 agonist efficacy in COPD. Thorax, 2016, 71(2): 118-125.
|
| 14. |
Martinez FJ, Rabe KF, Sethi S, et al. Effect of roflumilast and inhaled corticosteroid/long-acting β2-agonist on chronic obstructive pulmonary disease exacerbations (RE(2)SPOND). A randomized clinical trial. Am J Respir Crit Care Med, 2016, 194(5): 559-567.
|
| 15. |
Albert RK, Connett J, Bailey WC, et al. Azithromycin for prevention of exacerbations of COPD. N Engl J Med, 2011, 365(8): 689-698.
|
| 16. |
Bafadhel M, McKenna S, Terry S, et al. Blood eosinophils to direct corticosteroid treatment of exacerbations of chronic obstructive pulmonary disease: a randomized placebo-controlled trial. Am J Respir Crit Care Med, 2012, 186(1): 48-55.
|
| 17. |
Leuppi JD, Schuetz P, Bingisser R, et al. Short-term vs conventional glucocorticoid therapy in acute exacerbations of chronic obstructive pulmonary disease: the REDUCE randomized clinical trial. JAMA, 2013, 309(21): 2223-2231.
|
| 18. |
Masterton RG, Burley CJ. Randomized, double-blind study comparing 5- and 7-day regimens of oral levofloxacin in patients with acute exacerbation of chronic bronchitis. Int J Antimicrob Agents, 2001, 18(6): 503-512.
|
| 19. |
The Global Initiative for Chronic Obstructive Lung Disease. 2018 global strategy for the diagnosis, management and prevention of COPD. (2017-11-19)[2017-12-19]. http://goldcopd.org/wp-content/uploads/2017/11/GOLD-2018-v6.0-FINAL-revised-20-Nov_WMS.pdf.
|
